{"name":"Dynacure","slug":"dynacure","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQUUJQNWt3MElBU0t4Z09XT29zN0N5M1FVekd1RFo1T1F3Wk83Ml9qeDVBal95Q1JIWFpfSTJYTGlDMkpfM1A5MGp6YUtucGZINW93RXFTblNLTjBES3A2M00yc3B0T0JobFgxekRlWEd2MUdFOVJOUENyUjNoS0djYVFPZWhoVUFyVVhPTmVGQnpwcml3aHc?oc=5","date":"2024-05-08","type":"pipeline","source":"The Shoreline Beacon","summary":"New lab opens May 13 in Port Elgin pharmacy - The Shoreline Beacon","headline":"New lab opens May 13 in Port Elgin pharmacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPdml1Mk9vZ01xX2dTRTVlcjNVNW1MLVpPZkxDTHh1SWlvd0thTHFxSm1GQlQzcUQzUHdqYVIyRzdIVnEtbUkyeV9XTnBoVU4yV0NFaUlBTmlzMkRuY1lyWGpKVzNNZ0p3V0c5ZllRNnNTbnd3V29MdnNlSU5fSVIyNFZET0FodUNDSFIxaHdJYkp4aWQ3UHViMThuOWIyTGVzeVhtZHd5Q01TeDNZN1NN?oc=5","date":"2023-03-02","type":"pipeline","source":"Fierce Biotech","summary":"Flamingo folds Dynacure into its flamboyance to wade through biotech markets together - Fierce Biotech","headline":"Flamingo folds Dynacure into its flamboyance to wade through biotech markets together","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPWnF2NndvckVfcEtDOVNHTmZTZHZnSGptdTFYR2pSS3pHY3U3Ny02UThPeDQ4cW16T19NTkpBUHRRc25Zd1MtbUhVSXJWMEM3aG9vdVUtMUxhZTBHNGNDR2c0NkpGWGxxUjdvLWkxSzU3RWZNZ0FfU0dqMmpyLVBTNG0taFp1cXR2TVF0djF0VVkxSWNzTzlJcjFVQjdETFkt?oc=5","date":"2022-07-07","type":"pipeline","source":"Fierce Biotech","summary":"Dynacure calls it quits on top asset to the dismay of the myotubular myopathy community - Fierce Biotech","headline":"Dynacure calls it quits on top asset to the dismay of the myotubular myopathy community","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxONGdia1QydVFCeXNkc0hBSlRyNzAtYncxczVzSVRlUGhzUnV1TzRkdWhCalc4R2tZTkd4R09BTmJNZ2dCbEcxeVlOSlIxb1EzRnlFYVJlNkNQT1I5ZE55TVdvS08zUEZvN3N5NnJtVmdrSlhxZDhzUVFaeERRWmVNU2JCcjFtaFJRT0s4QW5xQ1BXbUxnd0hidDhaT1NtbnpxQTgtZFRyaDVncTNIcnk2S3NyZ1FEVXNNX283ZTN0S1hPMkdhQ3BZOVpUY21Fd1lHbDlXQWgzMA?oc=5","date":"2021-11-10","type":"deal","source":"PR Newswire","summary":"Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku - PR Newswire","headline":"Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNQS15T0I4a2F3Z1ZIQ1lIVldORzFXOVJIYXZhTnAwQTI4OVcyazRMLTlLTU5YRjh2TTlGOTllc29LZ3hsak9tZmJaT21jMmhmaGNqbXptSzlRcjBSRkJlWk1aNzdnWGJnWEI2b2N4S2g1LTVpTWFqNDdxaFNBemJnUncxUUhJQ3pQVDN4cVVUMEhvNmJLZjlNNHowdmsydkprNmlOczRkZkd5VnNvMmV0X3NmdkdROHh5eHU2RlhqWTJ5clJYLXhRNEZILTFqNi0zRU5fNGlKejBzQQ?oc=5","date":"2021-01-26","type":"patent","source":"BioSpace","summary":"Dynacure Announces Issuance of U.S. Patent for DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM) - BioSpace","headline":"Dynacure Announces Issuance of U.S. Patent for DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOTjRBem5nQXR0ZGk1cEFMM0tvc2VONjU5RHhvVmdmTE5pUVlsa1o5cFpGRGFZVGRFZHFrVURJcUE0cWZiRGxhSkRoWEN4Y3ZfcjJWZ21MR3FEMWMwWFJnaEtGd0pmdjFscnJhNW1fNXZoSHJ3dEtzZW1FSGRPYy16MFAxVl9HeDA?oc=5","date":"2018-07-06","type":"pipeline","source":"cen.acs.org","summary":"Dynacure launches with $55 million and Ionis antisense oligonucleotide drug - cen.acs.org","headline":"Dynacure launches with $55 million and Ionis antisense oligonucleotide drug","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}